Qualitek Labs (QLL) | Financial Analysis & Statements
Qualitek Labs Ltd. Small-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Income Metrics
Balance Sheet Metrics
Total Assets
1.6B
Total Liabilities
651.4M
Shareholders Equity
927.8M
Debt to Equity
0.70
Cash Flow Metrics
Revenue & Profitability Trend
Annual Income Flow
2025
Qualitek Labs Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 702.3M | 291.8M | 191.4M | 120.1M | 63.5M |
| Cost of Goods Sold | 102.0M | 57.8M | 42.5M | 18.9M | 15.1M |
| Gross Profit | 600.2M | 234.1M | 148.9M | 101.2M | 48.5M |
| Gross Margin % | 85.5% | 80.2% | 77.8% | 84.2% | 76.3% |
| Operating Expenses | |||||
| Research & Development | - | - | - | - | - |
| Selling, General & Administrative | 25.0M | 17.8M | 11.1M | 13.3M | 6.0M |
| Other Operating Expenses | 122.2M | 58.9M | 36.7M | 27.3M | 14.5M |
| Total Operating Expenses | 147.2M | 76.7M | 47.8M | 40.6M | 20.5M |
| Operating Income | 125.0M | 67.4M | 45.7M | 7.8M | 4.0M |
| Operating Margin % | 17.8% | 23.1% | 23.9% | 6.5% | 6.3% |
| Non-Operating Items | |||||
| Interest Income | 2.1M | 698.0K | 588.0K | 112.0K | 0 |
| Interest Expense | 20.9M | 9.1M | 6.9M | 2.8M | 70.0K |
| Other Non-Operating Income | - | - | - | - | - |
| Pre-tax Income | 104.2M | 58.2M | 39.4M | 4.9M | 3.9M |
| Income Tax | 27.3M | 15.2M | 9.9M | 642.0K | 2.3M |
| Effective Tax Rate % | 26.2% | 26.0% | 25.3% | 13.2% | 60.4% |
| Net Income | 76.8M | 43.1M | 29.4M | 4.2M | 1.5M |
| Net Margin % | 10.9% | 14.8% | 15.4% | 3.5% | 2.4% |
| Key Metrics | |||||
| EBITDA | 170.9M | 81.5M | 55.9M | 12.9M | 7.4M |
| EPS (Basic) | ₹7.08 | ₹7.46 | ₹3.99 | ₹0.57 | ₹0.21 |
| EPS (Diluted) | ₹7.08 | ₹7.46 | ₹3.99 | ₹0.57 | ₹0.21 |
| Basic Shares Outstanding | 8893595 | 5772000 | 7371900 | 7371900 | 7371900 |
| Diluted Shares Outstanding | 8893595 | 5772000 | 7371900 | 7371900 | 7371900 |
Income Statement Trend
Join Our India Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Qualitek Labs Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 43.1M | 4.1M | 3.5M | 279.0K | 1.4M |
| Short-term Investments | 8.6M | 13.6M | - | - | - |
| Accounts Receivable | 288.6M | 78.5M | 58.3M | 22.0M | 12.0M |
| Inventory | 26.5M | - | - | - | - |
| Other Current Assets | 8.2M | -1.0K | - | - | 1.0K |
| Total Current Assets | 426.1M | 117.1M | 85.9M | 66.9M | 25.4M |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 590.0M | 295.1M | 0 | - | - |
| Goodwill | 663.6M | - | - | - | - |
| Intangible Assets | 2.9M | - | - | - | - |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 46.9M | -2.0K | -1.0K | -1.0K | -2.0K |
| Total Non-Current Assets | 1.2B | 388.8M | 310.0M | 143.3M | 117.9M |
| Total Assets | 1.6B | 505.9M | 395.9M | 210.2M | 143.3M |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 72.8M | 23.8M | 36.7M | 15.7M | 23.8M |
| Short-term Debt | 194.3M | 20.8M | 131.1M | 171.5M | 109.7M |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | 228.0K | 23.2M | 1.0K | 6.7M | 8.4M |
| Total Current Liabilities | 325.8M | 68.8M | 186.9M | 198.7M | 146.0M |
| Non-Current Liabilities | |||||
| Long-term Debt | 308.6M | 101.7M | 103.4M | 2.0M | 2.5M |
| Deferred Tax Liabilities | 7.4M | 8.6M | 5.9M | 391.0K | 58.0K |
| Other Non-Current Liabilities | -1.0K | -1.0K | -1.0K | - | - |
| Total Non-Current Liabilities | 325.6M | 112.6M | 110.0M | 2.7M | 2.7M |
| Total Liabilities | 651.4M | 181.4M | 296.9M | 201.4M | 148.7M |
| Equity | |||||
| Common Stock | 99.8M | 73.7M | 54.1M | 4.6M | 100.0K |
| Retained Earnings | 145.0M | 82.0M | 39.0M | -1.2M | -5.4M |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 927.8M | 324.5M | 99.0M | 8.8M | -5.3M |
| Key Metrics | |||||
| Total Debt | 502.9M | 122.5M | 234.5M | 173.5M | 112.2M |
| Working Capital | 100.2M | 48.3M | -101.0M | -131.9M | -120.6M |
Balance Sheet Composition
Qualitek Labs Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | 104.2M | 58.2M | 39.4M | 4.6M | 3.9M |
| Depreciation & Amortization | - | - | - | - | - |
| Stock-Based Compensation | - | - | - | - | - |
| Working Capital Changes | -63.0M | -14.0M | 5.2M | -44.2M | -1.8M |
| Operating Cash Flow | 58.0M | 53.0M | 51.4M | -36.9M | 2.2M |
| Investing Activities | |||||
| Capital Expenditures | -233.2M | -100.0M | -173.2M | -17.7M | -60.6M |
| Acquisitions | -376.5M | -86.7M | -148.5M | - | 30.0K |
| Investment Purchases | - | - | - | - | - |
| Investment Sales | 15.6M | - | - | - | - |
| Investing Cash Flow | -602.8M | -186.7M | -321.7M | -17.7M | -60.6M |
| Financing Activities | |||||
| Share Repurchases | - | - | - | - | - |
| Dividends Paid | - | - | - | - | - |
| Debt Issuance | - | 26.5M | 142.6M | 0 | - |
| Debt Repayment | - | -28.2M | -41.2M | -519.0K | -61.4M |
| Financing Cash Flow | 548.9M | 70.5M | 111.6M | 71.2M | 48.3M |
| Free Cash Flow | -128.5M | -48.3M | -101.0M | -69.1M | -47.1M |
| Net Change in Cash | 4.1M | -63.2M | -158.7M | 16.6M | -10.1M |
Cash Flow Trend
Qualitek Labs Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
37.58
Price to Book
2.57
Price to Sales
5.12
Profitability Ratios
Profit Margin
8.97%
Operating Margin
15.25%
Return on Equity
12.27%
Return on Assets
7.21%
Financial Health
Current Ratio
1.31
Debt to Equity
50.78
Beta
-0.11
Per Share Data
EPS (TTM)
₹9.58
Book Value per Share
₹140.22
Revenue per Share
₹78.96
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| QLL | 3.6B | 37.58 | 2.57 | 12.27% | 8.97% | 50.78 |
| Dr. Lal PathLabs | 238.9B | 46.16 | 10.20 | 22.08% | 19.84% | 6.44 |
| Sai Life Sciences | 217.1B | 64.75 | 9.48 | 7.99% | 15.34% | 18.40 |
| Vimta Labs | 20.5B | 28.76 | 5.13 | 17.78% | 18.82% | 1.63 |
| Krsnaa Diagnostics | 19.8B | 24.69 | 2.13 | 8.79% | 10.49% | 30.96 |
| Suraksha Diagnostic | 14.7B | 45.27 | 6.37 | 15.14% | 11.32% | 51.30 |
Financial data is updated regularly. All figures are in the company's reporting currency.





